EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 30 (Novembre 2014) Hors série n°2 Med Sci (Paris), 30 (2014) 14-17 References
Free Access
Issue
Med Sci (Paris)
Volume 30, Novembre 2014
2e colloque de l’ITMO Santé publique – Médecine « personnalisée » et innovations biomédicales : enjeux de santé publique, économiques, éthiques et sociaux (Paris, 5 décembre 2013)
Page(s) 14 - 17
Section Session 1. Les grands enjeux de santé publique, économiques, éthiques et sociaux de la médecine personnalisée
DOI https://doi.org/10.1051/medsci/201430s203
Published online 17 November 2014
  1. Pennisi E. Breakthrough of the year. Human genetic variation. Science 2007 ; 318 : 1842–1843. [CrossRef] [PubMed] [Google Scholar]
  2. Kaiser J. Breakthrough of the year. It’s all about me. Science 2007 ; 318 : 1843. [CrossRef] [PubMed] [Google Scholar]
  3. Open letter to the scientific community. 23andMe, 2008, available at: www.23andme.com/for/scientists. [Google Scholar]
  4. Collins FS. 2005 William Allan award address. No longer just looking under the lamppost. Am J Hum Genet 2006 ; 79 : 421–426. [CrossRef] [PubMed] [Google Scholar]
  5. Neel JV. Editorial. Genet Epidemiol 1984 ; 1 : 5–6. [CrossRef] [Google Scholar]
  6. Rao DC. Editorial comments. Genet Epidemiol 1984 ; 1 : 1–3. [CrossRef] [Google Scholar]
  7. Clerget-Darpoux F. La folle course au gène de la folie. La Recherche 1998 ; 311 : 44–47. [Google Scholar]
  8. Feingold J. Maladies multifactorielles : un cauchemar pour le généticien. Med Sci (Paris) 2005 ; 21 : 927–933. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009 ; 461 : 747–753. [CrossRef] [PubMed] [Google Scholar]
  10. Lewontin RC. Annotation: the analysis of variance and the analysis of causes. Am J Human Genet 1974 ; 26 : 400–411. [Google Scholar]
  11. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012 ; 380 : 1590–1605. [CrossRef] [PubMed] [Google Scholar]
  12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001 ; 411 : 599–603. [CrossRef] [PubMed] [Google Scholar]
  13. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010 ; 42 : 1118–1125. [CrossRef] [PubMed] [Google Scholar]
  14. Quelle valeur accorder aux prédictions de risques pour les maladies multifactorielles ? Société française de génétique humaine, 2010. [Google Scholar]
  15. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003 ; 3 : 202–214. [CrossRef] [PubMed] [Google Scholar]
  16. D’Andrea G, D’Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005 ; 105 : 645–649. [CrossRef] [PubMed] [Google Scholar]
  17. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 ; 112 : 1022–1027. [CrossRef] [PubMed] [Google Scholar]
  18. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009 ; 5 : e1000433. [CrossRef] [PubMed] [Google Scholar]
  19. Flockhart DA, O’Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008 ; 10 : 139–150. [CrossRef] [PubMed] [Google Scholar]
  20. Blue cross and blue shield of Kansas. Genetic testing for warfarin dose. BCBSK, 2010. [Google Scholar]
  21. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013 ; 369 : 2283–2293. [CrossRef] [PubMed] [Google Scholar]
  22. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013 ; 369 : 2304–2312. [CrossRef] [PubMed] [Google Scholar]
  23. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013 ; 369 : 2294–2303. [CrossRef] [PubMed] [Google Scholar]
  24. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 2013 ; 369 : 2345–2346. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.